Bebtelovimab

Bebtelovimab a human IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19 ((the IC50 value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL) ) . Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy[1][2].

Product Specifications

CAS Number

[2578319-11-4]

Product Name Alternative

LY-3853113; LY-COV1404

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bebtelovimab.html

Purity

97.41

Solubility

10 mM in DMSO|H2O

Smiles

[Bebtelovimab]

Molecular Weight

(143.82 kDa)

References & Citations

[1]Shertel T, et al. Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. Transplantation. 2022 Oct 1;106 (10) :e463-e464.|[2]Bebtelovimab. IMGT/mAb-DB.|[3]Westendorf K, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv [Preprint]. 2022 Mar 24:2021.04.30.442182.